Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

Jack D. Scott, Michael W. Miller, Sue‐Ing Lin et al.|Journal of Medicinal Chemistry|2017

Cited by 147